Navigation Links
Valensa to Market Neptune Krill Oil NKO(R) Formulations for Joint Health and Eye Health Dietary Supplements
Date:10/6/2009

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Valensa International (Eustis, FL USA) announced today that it has reached agreement with Neptune Technologies & Bioressources Inc. (Laval, Quebec, CANADA) for an exclusive, worldwide license to incorporate and market Neptune Krill Oil NKO® in condition-specific dietary supplement formulas targeting eye health and joint health. Valensa plans on using the unique biofunctional properties of the highly bioavailable Omega-3 phospholipids in NKO® in conjunction with several of its proprietary ingredients such as Zanthin® Natural Astaxanthin, extending its current platform of patented eye health formulations. Valensa has also developed and applied for IP protection for a new and revolutionary range of joint and eye health formulations featuring NKO® and other ingredients. Valensa is in discussions with customers and plans to launch the new patent-pending eye and joint health formulations during the first quarter of 2010. The company is currently conducting clinical trials to demonstrate the effectiveness of these new formulations. The wholesale US markets for eye health and joint health formulations are estimated at $60 million and $712 million respectively.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, NKO® is an ideal ingredient for the development of new supplement formulations for the company's signature eye health portfolio as well as the joint health market. "In the area of Omega-3s, NKO® is by far the most effective product from a bioavailability standpoint and NKO® is manufactured to quality standards that are in line with Valensa's previously stated commitment to the market. Based on the completed clinical trials on NKO® to date, and the new trials we are currently conducting, we are excited about the opportunity to work with Neptune Technologies to market and promote truly innovative eye health and joint health formulations," he said. Moerck wen
'/>"/>

SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Astaxanthin Stability Breakthrough Achieved by Valensa
2. Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development
3. Valensa Completes Second Expansion of Astaxanthin Capacity
4. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
5. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
6. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
7. Michigan Society for Healthcare Planning and Marketing to Hold Fall Conference
8. bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
9. Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
10. Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services
11. Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... ... David O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information ... is eager to help the college expand its reach and impact through innovative technologies ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... Sierra Madre, CA (PRWEB) , ... August 28, ... ... alternative solutions to wound center management, Decatur County Memorial Hospital recently transitioned management ... model of Wound Center Management for their outpatient wound center. , ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, today,announced that it has entered into definitive ... of 8,750,000 shares of,its common stock at $2.40 ... purchase 3,500,000 shares of common stock at an,exercise ...
... Respectively, Over Prior Year ... Period-, EXTON, Pa., ... for its second quarter and six,months of fiscal year 2008., Second Quarter ... income, increased 14% to $19.6 million in the Company,s second,fiscal quarter ended December ...
... Matthew L. Myers ... Tobacco-Free Kids, WASHINGTON, Jan. 24 The following statement,was ... A new global survey released by the U.S. Centers ... use, and even higher,rates of exposure to secondhand smoke, among ...
... 24 Karen Ignagni, President,and CEO of ... statement on,the Institute of Medicine,s (IOM) recommendation ... the effectiveness of healthcare products and,services:, ... deserve to know not only what medical ...
... day low price philosophy helps customers save more ... compared to prescription retail price, BENTONVILLE, Ark., ... recent prescription to over-the-counter (OTC) approved,drug, Zyrtec(R) (cetirizine ... Wal-Mart will offer eight different OTC Zyrtec products, ...
... Department of,Health and Human Services (HHS) Secretary ... standards developed by the Healthcare Information,Technology Standards ... advanced three,of its "Interoperability Specifications" to help ... a Nationwide Health Information Network in,the United ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 2Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 3Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 4Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 5Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 6Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 7Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 8Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 9Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 10Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 11Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 12Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 13Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 2Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 3Health News:Wal-Mart Becomes One of the First to Offer Over-the-Counter Zyrtec 2Health News:Wal-Mart Becomes One of the First to Offer Over-the-Counter Zyrtec 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... , ... a new market research report is available in its ... Market Review , http://www.reportlinker.com/p0164247/Insulin-Pumps-External---A-World-Market-Review.html , Insulin ... better control over diabetes, when compared to other forms ...
... , BELLEVUE, Wash., Dec. 1 ... retailer of health, beauty, vision, and pharmacy products, today announced ... orders were the highest in company history. This holiday season ... featured more special offers than in previous years and their ...
Cached Medicine Technology:Reportlinker Adds Insulin Pumps (External) - A World Market Review 2Reportlinker Adds Insulin Pumps (External) - A World Market Review 3Reportlinker Adds Insulin Pumps (External) - A World Market Review 4drugstore.com, inc. Has Best Day Ever on Cyber Monday 2drugstore.com, inc. Has Best Day Ever on Cyber Monday 3
Colloidal Gold Conjugated, Protein A - 12 OD...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: